Mild obstructive sleep apnea does not modulate baroreflex sensitivity in adult patients

Henry Blomster1
Tomi P Laitinen2
Juha EK Hartikainen3,6
Tiina M Laitinen2
Esko Vanninen3
Helena Gylling4,8
Johanna Sahlan1
Jouko Kokkarinen5
Jukka Randell5
Juha Seppä1
Henri Tuomilehto4,7

1Department of Otorhinolaryngology, Institute of Clinical Medicine, 2Department of Clinical Physiology and Nuclear Medicine, 3Department of Internal Medicine, 4Department of Clinical Nutrition, School of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, 5Department of Respiratory Medicine, 6Heart Center, Kuopio University Hospital, 7Oivauni Sleep Clinic, Kuopio, 8Department of Medicine, Division of Internal Medicine, University of Helsinki, Helsinki, Finland

Correspondence: Henry Blomster
Department of Otorhinolaryngology, Kuopio University Hospital, PO Box 1777, FIN-70211 Kuopio, Finland
Tel +358 17 173 270
Fax +358 17 173 244
Email henry.blomster@kuh.fi


Introduction
Obstructive sleep apnea (OSA) is a common sleep disturbance affecting approximately 15%–25% of the population in the working-aged group, and has been found to be an independent risk factor for increased morbidity and mortality.1-2 Epidemiological studies have demonstrated a strong link between OSA and cardiovascular diseases such as hypertension, coronary artery disease, atrial fibrillation, stroke, and heart failure.3-5

Sympathetic activation has been proposed to be an important factor in the development of these diseases in patients with OSA.6-8 It has been postulated that the sympathetic nervous system is activated in response to stimulation of chemoreceptors induced by intermittent asphyxia and hypoxemia as well as by repeated arousals associated with OSA.9-11 There are several reports of sympathetic activation in severe OSA, as evidenced by depressed baroreceptor reflex sensitivity (BRS).9,11-20 Impaired BRS has been used as a marker of cardiac autonomic dysfunction in many serious diseases,
including diabetes, chronic heart failure, and coronary artery disease.\textsuperscript{21–23} Depressed BRS has been found to be a significant predictor of arrhythmic death in patients recovering from acute myocardial infarction.\textsuperscript{22,24–26}

OSA is a chronic, insidious disease that can progress independently of other risk factors, including weight gain,\textsuperscript{1,27,28} and in particular, the more severe stages of OSA have been linked to an increased risk of cardiovascular morbidity and mortality. However, little is known about the stage of OSA at which the cardiovascular changes appear. It is known that BRS is impaired in the severe stages of OSA, a phenomenon that is independent of obesity. Surprisingly, there have been very few studies examining this issue, and these have been inconclusive, perhaps due to the small sample sizes. Thus, there is no firm evidence, whether BRS may be disturbed already in the early stages of the disease, ie, in mild OSA\textsuperscript{12} or even in snoring patients without OSA.\textsuperscript{29–31} To address this issue, we conducted the largest study to date determining BRS in patients with mild OSA and body weight-matched non-OSA controls.

**Materials and methods**

**Design overview**

The objective of the study was to compare BRS in patients with mild OSA (apnea-hypopnea index [AHI] 5–15/hour) and non-OSA subjects (AHI <5/hour). Our working hypothesis was that BRS would be impaired already in snorers with mild OSA. The patients were given oral and written information about the trial protocol and they provided their written consent. The study protocol was approved by the research ethics committee of the Northern Savo Hospital District and is registered at ClinicalTrials.gov with the identifier NCT00486746.

**Patients**

The study was conducted in a single center, ie, Kuopio University Hospital, Finland. All the study subjects were consecutively recruited from the patients referred from the primary health care centers to the outpatient clinics of otorhinolaryngology and respiratory medicine of the Kuopio University Hospital due to a clinical suspicion of sleep-disordered breathing. The recruitment started in October 2004 and ended in December 2006. Patients were assigned to undergo nocturnal cardiorespiratory monitoring. The weight and height were recorded, and the upper airway structure of each patient was reviewed. The inclusion criteria in the OSA group were: working age (18–65 years); body mass index 28–40 kg/m\(^2\); and AHI 5–15 events/hour. We excluded patients on any active treatment for OSA, as well as pregnant women and those with chronic kidney, thyroid, or liver disease. The control group consisted of subjects who fulfilled the first two inclusion criteria but did not exhibit any signs of OSA (AHI <5 events/hour, Figure 1).

**Procedures and measurements**

Nocturnal six-channel ambulatory cardiorespiratory monitoring (Embla, Broomfield, CO, USA) at home was conducted in accordance with accepted guidelines for diagnosing OSA.\textsuperscript{32} Nasal flow was assessed by a nasal flow detector, thoracic and abdominal movements were estimated by two piezoelectric belts, oxygen saturation and heart rate were determined by finger pulse oximetry, and body position was monitored. Apnea was defined as a cessation (≥90%) of airflow for ≥10 seconds. Hypopnea was defined as a reduction (≥30%) of airflow for ≥10 seconds with oxygen desaturation ≥4%. The AHI was defined as the number of apneas and hypopneas per hour, and mild OSA was defined as AHI 5–15 events/hour.\textsuperscript{33,34} Other parameters such as arterial oxygen saturation, time and percentage with arterial oxygen saturation below 90%, and heart rate were assessed. Many routine biochemical parameters were also measured.

**Assessment of BRS**

BRS was always evaluated between 10 am and 2 pm using a modification of the method originally described by Smyth et al.\textsuperscript{35} In brief, a bolus injection of phenylephrine 150 µg was administered into the antecubital vein to produce a rapid increase in blood pressure and a concomitant reduction in heart rate (increase in R-R interval [RRI]). Beat-to-beat RRI values were plotted against systolic arterial pressure (SAP) values from the preceding cardiac cycle [ie, RRI(1) vs SAP(1 – 1)] during the period in which blood pressure increased after injection of phenylephrine. A linear regression analysis between RRI(1) and SAP(1 – 1) was performed and can be expressed as follows: RRI(1) (ms/mmHg), where \(i\) is one individual cardiac cycle and \(i – 1\) is the cardiac beat preceding the \(i\) beat. The slope of the regression line (\(b\)) represents BRS, \(a\) is a constant, and \(b\) represents the coefficient derived from the linear regression (first-order equation, Figure 2).

Only tests with correlation coefficients of \(r > 0.80\) or that were statistically significant (\(P < 0.05\)) were accepted. The phenylephrine test was repeated at 10-minute intervals up to five times in order to obtain three acceptable measurements. The average of the three measurements was used for assessment of BRS. In two cases, we were not able to obtain any acceptable BRS values because of technical problems or ectopic beats. Further, BRS was assessed in proportion to
age-related and sex-related reference values, with these being calculated as percentages. The coefficient of variation and correlation coefficient of two measurements performed at 3-month intervals were 7.4% and 0.903, respectively.

Blood pressure and anthropometric measurements
Blood pressure was measured from the right arm in the sitting position, and recorded three times, after 10 minutes of rest, using a standard sphygmomanometer. The mean value of the measurements was used for analyses. At the study site, a trained nurse measured height, weight, waist circumference, and blood pressure.

Statistical analysis
Mean values and standard deviations were calculated to describe the characteristics of the two study groups. The Student’s t-test and Fisher’s Exact test were used to assess equality between the groups. The normality of the variables was determined using the Kolmogorov-Smirnov test. For variables with a right skewed distribution, a logarithmic transformation was applied before further analysis. We...
report medians and ranges for nonparametric variables in Tables 1 and 2. The differences in risk are reported as odds ratios with 95% confidence intervals. In the secondary analysis of continuous variables between the OSA and non-OSA groups, the unequal sample size had a power of 80% to detect a statistical significance of 0.05 (effect size 0.51) for a difference between the groups. All characteristics and variables were analyzed with Statistical Package for Social Sciences version 19 software (SPSS Inc., Chicago, IL, USA).

**Results**

The body mass index, percentage body fat, blood pressure, fasting glucose, insulin, and lipid levels did not differ between the OSA patients and non-OSA subjects (Table 1). Patients in the OSA group were slightly but significantly older than the non-OSA population (50.3±9.3 years vs 45.7±11.1 years, *P*=0.02).

The absolute BRS values (9.97±6.70 ms/mmHg vs 10.51±7.16 ms/mmHg, *P*=0.67) as well as BRS values proportional to age-related and sex-related reference values (91.4%±22.7% vs 92.2%±21.8%, *P*=0.84) did not differ between the patients with mild OSA and the non-OSA subjects (Table 2). Furthermore, 6.2% of participants in the OSA group and 2.1% in the non-OSA group had BRS <50% of the sex-specific reference value (*P*=0.29).

In both groups, men had higher BRS values than women (11.0±7.0 ms/mmHg vs 7.2±5.0 ms/mmHg, *P*=0.02 and 12.8±7.8 ms/mmHg vs 7.6±5.3 ms/mmHg, *P*=0.01, respectively). Non-OSA subjects had higher fasting serum high-density lipoprotein cholesterol levels (*P*<0.05), higher average oxygen saturation levels (*P*<0.05), and a
lower AHI (P<0.001) when compared with OSA patients (Table 1). In both groups, BRS was inversely correlated with age, systolic blood pressure, and percentage body fat (Table 3).

### Discussion

The main finding of this study was that BRS as measured by the intravenous phenylephrine test during wakefulness was not impaired in patients with mild OSA when compared with non-OSA subjects. Only 6% of patients with mild OSA and 2% of non-OSA subjects displayed signs of impaired BRS.

### Table 1 Clinical characteristics in mild OSA and non-OSA groups

<table>
<thead>
<tr>
<th></th>
<th>Mild OSA (n=81)</th>
<th>Non-OSA (n=48)</th>
<th>Significance</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>50 (9)</td>
<td>46 (11)</td>
<td>0.02</td>
<td></td>
</tr>
<tr>
<td>Sex (male/female)</td>
<td>60/21</td>
<td>27/21</td>
<td>0.03</td>
<td></td>
</tr>
<tr>
<td>Time between sleep and BRS measurements (days)</td>
<td>72 (9)</td>
<td>96 (96)</td>
<td>0.17</td>
<td></td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>32.5 (3.0)</td>
<td>31.7 (3.7)</td>
<td>0.17</td>
<td></td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>130 (11)</td>
<td>132 (12)</td>
<td>0.40</td>
<td></td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>81 (8)</td>
<td>83 (10)</td>
<td>0.72</td>
<td></td>
</tr>
<tr>
<td>Fasting plasma glucose (mmol/L)</td>
<td>6.16 (1.9)</td>
<td>5.89 (1.1)</td>
<td>0.37</td>
<td></td>
</tr>
<tr>
<td>Fasting serum insulin (mU/L)</td>
<td>12.06 (5.99)</td>
<td>11.58 (5.67)</td>
<td>0.68</td>
<td></td>
</tr>
<tr>
<td>Fasting serum cholesterol (mmol/L)</td>
<td>4.70 (0.82)</td>
<td>5.00 (0.89)</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td>Fasting serum HDL cholesterol (mmol/L)</td>
<td>1.06 (0.29)</td>
<td>1.19 (0.39)</td>
<td>0.02</td>
<td></td>
</tr>
<tr>
<td>Fasting serum triglycerides (mmol/L)</td>
<td>1.73 (1.11)</td>
<td>1.54 (0.89)</td>
<td>0.32</td>
<td></td>
</tr>
<tr>
<td>Hypertension (n)</td>
<td>34</td>
<td>13</td>
<td>0.07</td>
<td></td>
</tr>
<tr>
<td>Antihypertensive medication (n)</td>
<td>38</td>
<td>17</td>
<td>0.14</td>
<td></td>
</tr>
<tr>
<td>Hypercholesterolemia (n)</td>
<td>26</td>
<td>5</td>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td>Hypercholesterolemia medication (n)</td>
<td>26</td>
<td>5</td>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td>Coronary artery disease (n)</td>
<td>3</td>
<td>0</td>
<td>0.24</td>
<td></td>
</tr>
<tr>
<td>Diabetes (n)</td>
<td>7</td>
<td>2</td>
<td>0.28</td>
<td></td>
</tr>
<tr>
<td>Diabetes medication (n)</td>
<td>7</td>
<td>1</td>
<td>0.13</td>
<td></td>
</tr>
<tr>
<td>Current smoker (n)</td>
<td>21</td>
<td>11</td>
<td>0.44</td>
<td></td>
</tr>
<tr>
<td>Apnea-hypopnea index</td>
<td>9.3 (3.3)</td>
<td>1.9 (1.4)</td>
<td>&lt;0.01</td>
<td></td>
</tr>
<tr>
<td>Mean oxygen saturation (%)</td>
<td>94.0 (1.4)</td>
<td>94.8 (1.7)</td>
<td>0.02</td>
<td></td>
</tr>
<tr>
<td>Time with oxygen saturation &lt;90% (minutes)</td>
<td>304.0</td>
<td>337.0</td>
<td>0.01</td>
<td></td>
</tr>
<tr>
<td>Percent time with oxygen saturation &lt;90%</td>
<td>4.6 (0.4)</td>
<td>1.8 (0.1)</td>
<td>0.04</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** The data are shown as the mean ± standard deviation, frequency, or median with range.

**Abbreviations:** BRS, baroreceptor reflex sensitivity; OSA, obstructive sleep apnea; SD, standard deviation; HDL, high-density lipoprotein.

### Table 2 Baroreflex sensitivity in mild OSA and non-OSA groups

<table>
<thead>
<tr>
<th></th>
<th>Mild OSA (n=81)</th>
<th>Non-OSA (n=48)</th>
<th>Significance</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baroreflex sensitivity in phenylephrine test (ms/mmHg)</td>
<td>9.97 (6.70)</td>
<td>10.51 (7.16)</td>
<td>0.67</td>
<td></td>
</tr>
<tr>
<td>Percentage of reference value matched for age and sex</td>
<td>91.4 (22.7)</td>
<td>92.2 (21.8)</td>
<td>0.84</td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** The data are shown as the mean ± standard deviation; the Student’s t-test for means.

**Abbreviations:** OSA, obstructive sleep apnea; SD, standard deviation.

There are several studies that have assessed BRS in patients with OSA. Regardless of the techniques used for measurement of BRS, most have demonstrated that severe OSA is associated with a reduction in BRS. Ward et al found that BRS was impaired during wakefulness in subjects with severe OSA which they assessed in three ways, ie, the sequence technique, the spectral transfer function technique, and the alpha index technique. Similarly, reductions in BRS were detected in patients with moderate-to-severe OSA using either the Valsalva technique or the nitroprusside test. In addition, there are studies using the sequence method reporting decreased nocturnal BRS in severe OSA. Further, it is known that treatment with continuous positive airway pressure improves BRS in OSA patients, suggesting that the impairment of BRS is reversible.

### Table 3 Univariate correlates of BRS values in mild OSA and non-OSA groups

<table>
<thead>
<tr>
<th></th>
<th>Mild OSA</th>
<th>Non-OSA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>-0.64*</td>
<td>-0.50*</td>
</tr>
<tr>
<td>Body mass index</td>
<td>-0.122</td>
<td>-0.027</td>
</tr>
<tr>
<td>Percentage body fat</td>
<td>-0.301*</td>
<td>-0.413*</td>
</tr>
<tr>
<td>Systolic blood pressure</td>
<td>-0.248*</td>
<td>-0.420*</td>
</tr>
<tr>
<td>Diastolic blood pressure</td>
<td>0.205</td>
<td>-0.157</td>
</tr>
<tr>
<td>Fasting plasma glucose</td>
<td>-0.261</td>
<td>-0.206</td>
</tr>
<tr>
<td>Fasting serum insulin</td>
<td>-0.118</td>
<td>-0.138</td>
</tr>
<tr>
<td>Fasting serum cholesterol</td>
<td>0.161</td>
<td>0.034</td>
</tr>
<tr>
<td>Fasting serum HDL cholesterol</td>
<td>0.134</td>
<td>-0.189</td>
</tr>
<tr>
<td>Fasting serum triglycerides</td>
<td>-0.136</td>
<td>-0.189</td>
</tr>
<tr>
<td>AHI</td>
<td>0.146</td>
<td>0.120</td>
</tr>
<tr>
<td>Mean oxygen saturation</td>
<td>0.297</td>
<td>-0.215</td>
</tr>
<tr>
<td>Time with oxygen saturation &lt;90%</td>
<td>-0.394</td>
<td>0.279</td>
</tr>
</tbody>
</table>

**Notes:** Values are shown as Pearson’s correlation coefficient and Spearman’s coefficient for variables that were not normally distributed; *statistically significant at P<0.05.

**Abbreviations:** AHI, apnea-hypopnea index; BRS, baroreceptor reflex sensitivity; OSA, obstructive sleep apnea; HDL, high-density lipoprotein.
The effect of mild-to-moderate OSA on BRS is less clear. In our study, assessment of BRS did not reveal any differences between patients with mild OSA and their non-OSA controls. This is in agreement with Ryan et al. In their study, BRS was lower in patients with severe OSA when compared with patients having mild-to-moderate OSA or non-OSA subjects. However, there was no difference in BRS between the patients with mild-to-moderate OSA and non-OSA subjects. In contrast, our findings and those of Ryan et al, Noda et al, and Ward et al reported reduced values of BRS in patients with mild-to-moderate OSA than those detected in healthy controls. Our study and that reported by Ryan et al used non-OSA snorers as the reference group, whereas the reference groups in the studies by Noda et al and Ward et al consisted of healthy controls, but this is unlikely to account for the differences in the results. There is a report that BRS does not differ in non-OSA snorers and healthy controls during wakefulness. Interestingly, in the study by Schöbel et al, BRS during the daytime was lower in patients with nocturnal snoring than in healthy non-snorers. However, BRS was not assessed with the phenylephrine technique, but calculated from spontaneous fluctuations of heart rate and blood pressure using the squared root of the ratio of heart rate variability and systolic blood pressure variability. BRS assessed with the phenylephrine method measures the heart rate response to an increase in blood pressure (vagal activation), whereas BRS assessed from spontaneous blood pressure fluctuations includes heart rate responses to both increased (vagal activation) and decreased (vagal withdrawal) blood pressure. Thus, although the phenylephrine method and BRS are based on spontaneous blood pressure oscillations and both assess autonomic reflexes induced by blood pressure change, they cannot be compared with each other.

The underlying mechanism responsible for the reduced BRS is believed to be sympathetic activation caused by nocturnal upper airway collapses, repetitive asphyxia resulting in hypoxia and arousals. In addition, hypoxia over time leading to enhanced chemoreceptor activity may also play a role in the chronic sympathetic activation. Severe OSA is associated with significant cardiovascular morbidity and mortality. Sympathetic activation is considered to be one of the key mechanisms linking OSA to cardiovascular morbidity and mortality. However, it is not clear at what stage of OSA the harmful changes in vascular function appear. We have demonstrated that endothelial function is well preserved in patients with mild OSA. On the other hand, mild OSA is associated with increased activation of the inflammatory system, a symptom that could be normalized by weight loss after successful lifestyle intervention. These findings indicate that the inflammatory system is more susceptible to OSA than cardiovascular regulation.

Decreased BRS is considered to be one of the early markers of autonomic dysfunction in many diseases, including hypertension, diabetes, chronic heart failure, and coronary artery disease. Recent studies have shown that BRS is decreased even in the early asymptomatic stages of coronary artery atherosclerosis, and impaired BRS predicted cardiovascular death in middle-aged subjects without cardiovascular disease. Therefore, this method was applied in our study to assess BRS. While this method has advantages for cardiovascular risk stratification, it has the drawback that, due to the intravenous administration of phenylephrine, it cannot be undertaken when the patient is asleep.

Our results indicate that BRS measured by the phenylephrine test may not be decreased in patients with mild OSA when compared with non-OSA controls. Since OSA has a natural tendency to worsen over time and severe OSA is known to be associated with increased cardiovascular mortality, intervention in the early stages of the disease is essential in order to prevent progression of the disease and development of serious comorbidities.

There are some limitations to this study. The control group consisted of patients referred to hospital due to suspicion of sleep-disordered breathing, ie, snoring. After careful testing, these patients did not show any signs of OSA. In addition, as mentioned earlier, there is a controversy as to whether BRS is sustained in non-OSA snorers so it is unlikely that using non-OSA snorers would introduce any bias in the interpretation of our results. In addition, the use of weight-matched groups meant that we had metabolic-matched groups, which is of crucial importance when assessing vascular function. The diagnosis of OSA was based on cardiorespiratory recordings from a single night. On the other hand, in routine practice, repeated recordings are extremely demanding, and the findings of single-night recordings have been found to be reliable in most patients. The patients in the OSA group were slightly older than in the non-OSA group and there were also more males in the OSA group. Since age and sex are important contributors to BRS, in addition to absolute BRS values, we used age-adjusted and sex-adjusted BRS values in these analyses.

In conclusion, BRS was found to be well preserved in patients with mild OSA. This suggests that cardiac autonomic...
dysfunction appears later along the progression to more severe stages of OSA.

Acknowledgments
The authors cordially acknowledge the members of the Kuopio Sleep Apnea Group, ie, Taina Poutiainen, Matti Pukkila, Tatu Kemppainen, Aki Ikonen, Ritva Vanninen, Heimo Vinnamäki, Keijo Peuhkurinen, Kari Punnonen, Kati Venäläinen, Riitta Pahkala, Erkki Soini, and Janne Martikainen. Marjo-Leena Hannila, who assisted with the statistical analysis, is also gratefully acknowledged. The study was funded by the Hospital District of Northern Savo, Kuopio University Hospital. The Organisation for Respiratory Health in Finland (HELI), Kuopio Breathing Association, Antti and Tyyne Soininen Foundation, Väinö and Laina Kivi Foundation, Finnish Anti-Tuberculosis Foundation, and Finnish Research Foundation of Otology also supported the study with grants. The funding sources had no role in the study design; collection, analysis, or interpretation of the data; or writing of the report.

Author contributions
All authors contributed significantly to the conception and design of the study, acquisition of data, analysis and interpretation of data; drafting and revising of the manuscript; and final approval and agreement of the version to be published.

Disclosure
The authors report no conflicts of interest in this work.

Reference


